In the Annals of Oncology this week, a team of South Korean researchers report a meta-analysis of the associations between aspirin use and lung cancer risk. The team analyzed data from 15 studies — six case-control studies and nine prospective cohort studies. They found no significant association between aspirin use and lung cancer risk in the cohort studies, but they did find a significant association in the case-control studies. However, they add, "in a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies, but not among seven high-quality studies." Overall, the authors write, "the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials."
Also in the Annals of Oncology this week, a team of US researchers report that a promoter polymorphism in the GRP78 gene could serve as a potential predictor for clinical outcome in gastric and colorectal cancer patients. The researchers had blood samples from 234 stage II or III colorectal cancer patients and formalin-fixed paraffin-embedded tissues of 137 patients with localized gastric adenocarcinoma. In analyzing polymorphisms in GRP78 in these samples, the team found that gastric cancer patients with the rs391957 polymorphism and either a C/T or T/T genotype are at a higher risk for tumor recurrence and death, compared with patients who have the polymorphism and the C/C genotype. In addition, colorectal cancer patients with the polymorphism and T/T genotype were at the highest risk for tumor recurrence. "These data provide the first evidence that the GRP78 rs391957 polymorphism can predict clinical outcome in localized gastric adenocarcinoma and locally advanced colorectal cancer patients," the authors write.